Summary:
- The FDA has accepted a supplemental biologics license application for lecanemab, a drug used to treat early Alzheimer's disease.
- The application is for a subcutaneous (under the skin) starting dose of lecanemab, which could make it easier for patients to receive the medication.
- Lecanemab has been granted priority review by the FDA, which means the review process will be faster than normal.